世界の多価連鎖球菌・肺炎球菌ワクチン市場インサイト及び予測(9価、13価、23価、その他)

◆英語タイトル:Global Polyvalent Streptococcus Pneumococcal Vaccines Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX10471)◆商品コード:QY22JLX10471
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:116
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥695,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,043,700見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,391,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、多価連鎖球菌・肺炎球菌ワクチンのグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に多価連鎖球菌・肺炎球菌ワクチンの世界市場のxxx%を占める「9価」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
多価連鎖球菌・肺炎球菌ワクチンの中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの多価連鎖球菌・肺炎球菌ワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

多価連鎖球菌・肺炎球菌ワクチンのグローバル主要企業には、GlaxoSmithKline、LG Chem、Merck、Panacea Biotec、AstraZeneca、Pfizer、Shire、Pnuvax Incorporated、Serum Institute、Shinogi、Shenzhen Kangtai Biological Products、SK Bioscience、Walvax Biotechnology、Eli Lilly、Abera、Sanofi、Genentechなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

多価連鎖球菌・肺炎球菌ワクチン市場は、種類と用途によって区分されます。世界の多価連鎖球菌・肺炎球菌ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
9価、13価、23価、その他

【用途別セグメント】
病院、地域クリニック、保健所、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 多価連鎖球菌・肺炎球菌ワクチン製品概要
- 種類別市場(9価、13価、23価、その他)
- 用途別市場(病院、地域クリニック、保健所、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の多価連鎖球菌・肺炎球菌ワクチン販売量予測2017-2028
- 世界の多価連鎖球菌・肺炎球菌ワクチン売上予測2017-2028
- 多価連鎖球菌・肺炎球菌ワクチンの地域別販売量
- 多価連鎖球菌・肺炎球菌ワクチンの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別多価連鎖球菌・肺炎球菌ワクチン販売量
- 主要メーカー別多価連鎖球菌・肺炎球菌ワクチン売上
- 主要メーカー別多価連鎖球菌・肺炎球菌ワクチン価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(9価、13価、23価、その他)
- 多価連鎖球菌・肺炎球菌ワクチンの種類別販売量
- 多価連鎖球菌・肺炎球菌ワクチンの種類別売上
- 多価連鎖球菌・肺炎球菌ワクチンの種類別価格
・用途別市場規模(病院、地域クリニック、保健所、その他)
- 多価連鎖球菌・肺炎球菌ワクチンの用途別販売量
- 多価連鎖球菌・肺炎球菌ワクチンの用途別売上
- 多価連鎖球菌・肺炎球菌ワクチンの用途別価格
・北米市場
- 北米の多価連鎖球菌・肺炎球菌ワクチン市場規模(種類別、用途別)
- 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの多価連鎖球菌・肺炎球菌ワクチン市場規模(種類別、用途別)
- 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の多価連鎖球菌・肺炎球菌ワクチン市場規模(種類別、用途別)
- 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の多価連鎖球菌・肺炎球菌ワクチン市場規模(種類別、用途別)
- 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの多価連鎖球菌・肺炎球菌ワクチン市場規模(種類別、用途別)
- 主要国別の多価連鎖球菌・肺炎球菌ワクチン市場規模(トルコ、サウジアラビア)
・企業情報
GlaxoSmithKline、LG Chem、Merck、Panacea Biotec、AstraZeneca、Pfizer、Shire、Pnuvax Incorporated、Serum Institute、Shinogi、Shenzhen Kangtai Biological Products、SK Bioscience、Walvax Biotechnology、Eli Lilly、Abera、Sanofi、Genentech
・産業チェーン及び販売チャネル分析
- 多価連鎖球菌・肺炎球菌ワクチンの産業チェーン分析
- 多価連鎖球菌・肺炎球菌ワクチンの原材料
- 多価連鎖球菌・肺炎球菌ワクチンの生産プロセス
- 多価連鎖球菌・肺炎球菌ワクチンの販売及びマーケティング
- 多価連鎖球菌・肺炎球菌ワクチンの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 多価連鎖球菌・肺炎球菌ワクチンの産業動向
- 多価連鎖球菌・肺炎球菌ワクチンのマーケットドライバー
- 多価連鎖球菌・肺炎球菌ワクチンの課題
- 多価連鎖球菌・肺炎球菌ワクチンの阻害要因
・主な調査結果

The polyvalent streptococcus pneumoniae vaccine is a vaccine that mainly prevents pneumonia caused by Streptococcus pneumoniae. It contains a variety of serotypes that often cause streptococcus pneumoniae infection. After vaccination, it can effectively reduce the risk of pneumonia infection.
Market Analysis and Insights: Global Polyvalent Streptococcus Pneumococcal Vaccines Market
Due to the COVID-19 pandemic, the global Polyvalent Streptococcus Pneumococcal Vaccines market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, 9-Valent accounting for % of the Polyvalent Streptococcus Pneumococcal Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Polyvalent Streptococcus Pneumococcal Vaccines market size is valued at US$ million in 2021, while the US and Europe Polyvalent Streptococcus Pneumococcal Vaccines are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Polyvalent Streptococcus Pneumococcal Vaccines landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Polyvalent Streptococcus Pneumococcal Vaccines include GlaxoSmithKline, LG Chem, Merck, Panacea Biotec, AstraZeneca, Pfizer, Shire, Pnuvax Incorporated and Serum Institute, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Polyvalent Streptococcus Pneumococcal Vaccines Scope and Segment
Polyvalent Streptococcus Pneumococcal Vaccines market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Polyvalent Streptococcus Pneumococcal Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
9-Valent
13-Valent
23-Valent
Others
Segment by Application
Hospital
Community Clinics
Public Health Agencies
Others
By Company
GlaxoSmithKline
LG Chem
Merck
Panacea Biotec
AstraZeneca
Pfizer
Shire
Pnuvax Incorporated
Serum Institute
Shinogi
Shenzhen Kangtai Biological Products
SK Bioscience
Walvax Biotechnology
Eli Lilly
Abera
Sanofi
Genentech
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Polyvalent Streptococcus Pneumococcal Vaccines Product Introduction
1.2 Market by Type
1.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 9-Valent
1.2.3 13-Valent
1.2.4 23-Valent
1.2.5 Others
1.3 Market by Application
1.3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Community Clinics
1.3.4 Public Health Agencies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Estimates and Forecasts 2017-2028
2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Estimates and Forecasts 2017-2028
2.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region
2.4.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2017-2022)
2.4.2 Global Sales Polyvalent Streptococcus Pneumococcal Vaccines by Region (2023-2028)
2.5 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region
2.5.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2017-2022)
2.5.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Manufacturers
3.1.1 Global Top Polyvalent Streptococcus Pneumococcal Vaccines Manufacturers by Sales (2017-2022)
3.1.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Polyvalent Streptococcus Pneumococcal Vaccines in 2021
3.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Manufacturers
3.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Manufacturers (2017-2022)
3.2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Polyvalent Streptococcus Pneumococcal Vaccines Revenue in 2021
3.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type
4.1.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Sales by Type (2017-2022)
4.1.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Sales by Type (2023-2028)
4.1.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Type (2017-2028)
4.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type
4.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Revenue by Type (2017-2022)
4.2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Revenue by Type (2023-2028)
4.2.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Type (2017-2028)
4.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Type
4.3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Type (2017-2022)
4.3.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application
5.1.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Sales by Application (2017-2022)
5.1.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Sales by Application (2023-2028)
5.1.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Sales Market Share by Application (2017-2028)
5.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application
5.2.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Historical Revenue by Application (2017-2022)
5.2.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Forecasted Revenue by Application (2023-2028)
5.2.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Revenue Market Share by Application (2017-2028)
5.3 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Application
5.3.1 Global Polyvalent Streptococcus Pneumococcal Vaccines Price by Application (2017-2022)
5.3.2 Global Polyvalent Streptococcus Pneumococcal Vaccines Price Forecast by Application (2023-2028)
6 North America
6.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
6.1.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
6.1.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
6.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
6.2.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
6.2.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
6.3 North America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
6.3.1 North America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
6.3.2 North America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
7.1.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
7.1.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
7.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
7.2.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
7.2.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
7.3 Europe Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
7.3.1 Europe Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
7.3.2 Europe Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
8.1.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
8.1.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
8.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
8.2.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
8.2.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
8.3 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Region
8.3.1 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Sales by Region (2017-2028)
8.3.2 Asia Pacific Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
9.1.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
9.1.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
9.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
9.2.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
9.2.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
9.3 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
9.3.1 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
9.3.2 Latin America Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Type
10.1.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Type (2017-2028)
10.1.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Type (2017-2028)
10.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Application
10.2.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Application (2017-2028)
10.2.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Application (2017-2028)
10.3 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Market Size by Country
10.3.1 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Sales by Country (2017-2028)
10.3.2 Middle East and Africa Polyvalent Streptococcus Pneumococcal Vaccines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Corporation Information
11.1.2 GlaxoSmithKline Overview
11.1.3 GlaxoSmithKline Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GlaxoSmithKline Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GlaxoSmithKline Recent Developments
11.2 LG Chem
11.2.1 LG Chem Corporation Information
11.2.2 LG Chem Overview
11.2.3 LG Chem Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 LG Chem Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 LG Chem Recent Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Overview
11.3.3 Merck Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck Recent Developments
11.4 Panacea Biotec
11.4.1 Panacea Biotec Corporation Information
11.4.2 Panacea Biotec Overview
11.4.3 Panacea Biotec Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Panacea Biotec Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Panacea Biotec Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 AstraZeneca Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AstraZeneca Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Shire
11.7.1 Shire Corporation Information
11.7.2 Shire Overview
11.7.3 Shire Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shire Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shire Recent Developments
11.8 Pnuvax Incorporated
11.8.1 Pnuvax Incorporated Corporation Information
11.8.2 Pnuvax Incorporated Overview
11.8.3 Pnuvax Incorporated Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pnuvax Incorporated Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pnuvax Incorporated Recent Developments
11.9 Serum Institute
11.9.1 Serum Institute Corporation Information
11.9.2 Serum Institute Overview
11.9.3 Serum Institute Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Serum Institute Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Serum Institute Recent Developments
11.10 Shinogi
11.10.1 Shinogi Corporation Information
11.10.2 Shinogi Overview
11.10.3 Shinogi Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shinogi Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shinogi Recent Developments
11.11 Shenzhen Kangtai Biological Products
11.11.1 Shenzhen Kangtai Biological Products Corporation Information
11.11.2 Shenzhen Kangtai Biological Products Overview
11.11.3 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Shenzhen Kangtai Biological Products Recent Developments
11.12 SK Bioscience
11.12.1 SK Bioscience Corporation Information
11.12.2 SK Bioscience Overview
11.12.3 SK Bioscience Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 SK Bioscience Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 SK Bioscience Recent Developments
11.13 Walvax Biotechnology
11.13.1 Walvax Biotechnology Corporation Information
11.13.2 Walvax Biotechnology Overview
11.13.3 Walvax Biotechnology Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Walvax Biotechnology Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Walvax Biotechnology Recent Developments
11.14 Eli Lilly
11.14.1 Eli Lilly Corporation Information
11.14.2 Eli Lilly Overview
11.14.3 Eli Lilly Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Eli Lilly Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Eli Lilly Recent Developments
11.15 Abera
11.15.1 Abera Corporation Information
11.15.2 Abera Overview
11.15.3 Abera Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Abera Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Abera Recent Developments
11.16 Sanofi
11.16.1 Sanofi Corporation Information
11.16.2 Sanofi Overview
11.16.3 Sanofi Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Sanofi Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Sanofi Recent Developments
11.17 Genentech
11.17.1 Genentech Corporation Information
11.17.2 Genentech Overview
11.17.3 Genentech Polyvalent Streptococcus Pneumococcal Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Genentech Polyvalent Streptococcus Pneumococcal Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Genentech Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Polyvalent Streptococcus Pneumococcal Vaccines Industry Chain Analysis
12.2 Polyvalent Streptococcus Pneumococcal Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Polyvalent Streptococcus Pneumococcal Vaccines Production Mode & Process
12.4 Polyvalent Streptococcus Pneumococcal Vaccines Sales and Marketing
12.4.1 Polyvalent Streptococcus Pneumococcal Vaccines Sales Channels
12.4.2 Polyvalent Streptococcus Pneumococcal Vaccines Distributors
12.5 Polyvalent Streptococcus Pneumococcal Vaccines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Polyvalent Streptococcus Pneumococcal Vaccines Industry Trends
13.2 Polyvalent Streptococcus Pneumococcal Vaccines Market Drivers
13.3 Polyvalent Streptococcus Pneumococcal Vaccines Market Challenges
13.4 Polyvalent Streptococcus Pneumococcal Vaccines Market Restraints
14 Key Findings in The Global Polyvalent Streptococcus Pneumococcal Vaccines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の多価連鎖球菌・肺炎球菌ワクチン市場インサイト及び予測(9価、13価、23価、その他)(Global Polyvalent Streptococcus Pneumococcal Vaccines Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。